The identification of specific mutations in a patient's tumor can guide treatment decisions. Targeted therapies, such as tyrosine kinase inhibitors and immune checkpoint inhibitors, are designed to specifically target the mutated proteins or pathways driving cancer growth. For instance, the presence of EGFR mutations in non-small cell lung cancer can make patients eligible for EGFR inhibitors, which are more effective than conventional chemotherapy.
